Comparison between Astonea Labs IPO and Speciality Medicines IPO.
Astonea Labs IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Speciality Medicines IPO is a SME Bookbuilding proposed to list at BSE SME.
| Astonea Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Oneview Corporate Advisors Pvt.Ltd. | Unistone Capital Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Skyline Financial Services Pvt.Ltd. |
| Market Maker | Basan Equity Broking Ltd. | Aikyam Capital Private Limited |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Astonea Labs IPO is up to ₹35.72 Cr whereas the issue size of the Speciality Medicines IPO is up to ₹27.28 Cr. The final issue price of Astonea Labs IPO is ₹135.00 per share and of Speciality Medicines IPO is ₹124.00 per share.
| Astonea Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹128.00 per share | ₹117.00 per share |
| Issue Price (Upper) | ₹135.00 per share | ₹124.00 per share |
| Issue Price (Final) | ₹135.00 per share | ₹124.00 per share |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ||
| Market Lot Size | 1000 shares | 1000 shares |
| Fresh Issue Size | 26,46,000 shares | 22,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹35.72 Cr | up to ₹27.28 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 26,46,000 shares | 22,00,000 shares |
| Issue Size Total (Amount) | up to ₹35.72 Cr | up to ₹27.28 Cr |
Astonea Labs IPO opens on May 27, 2025, while Speciality Medicines IPO opens on Mar 20, 2026. The closing date of Astonea Labs IPO and Speciality Medicines IPO is May 29, 2025, and Mar 24, 2026, respectively.
| Astonea Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| Anchor Bid Date | May 26, 2025 | |
| Issue Open | May 27, 2025 | Mar 20, 2026 |
| Issue Close | May 29, 2025 | Mar 24, 2026 |
| Basis Of Allotment (Tentative) | May 30, 2025 | Mar 25, 2026 |
| Initiation of Refunds (Tentative) | Jun 02, 2025 | Mar 27, 2026 |
| Credit of Share (Tentative) | Jun 02, 2025 | Mar 27, 2026 |
| Listing date (Tentative) | Jun 03, 2025 | Mar 30, 2026 |
| Anchor Lockin End date 1 | Jun 29, 2025 | |
| Anchor Lockin End date 2 | Aug 28, 2025 |
Astonea Labs IPO P/E ratio is 27.36, as compared to Speciality Medicines IPO P/E ratio of 9.27.
| Astonea Labs IPO | Speciality Medicines IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Standalone)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 98.42 | 59.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 72.3 | 43.44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 27.36 | 9.27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹141.90 Cr. | ₹108.94 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 37.86 | 37.85 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 22.95 | 33.39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.16 | 0.17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.93 | ₹13.38 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 31.83 | 28.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Astonea Labs IPO Retail Individual Investors (RII) are offered 9,27,000 shares while in Speciality Medicines IPO retail investors are offered 9,27,000 shares. Qualified Institutional Buyers (QIB) are offered 5,30,000 shares in Astonea Labs IPO and 21,000 shares in Speciality Medicines IPO.
| Astonea Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| Anchor Investor Reservation | 7,90,000 shares | 0 shares |
| Market Maker Reservation | 1,44,000 shares | 1,50,000 shares |
| QIB | 5,30,000 shares | 21,000 shares |
| NII | 3,99,000 shares | 10,89,000 shares |
| RII | 9,27,000 shares | 10,90,000 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 26,46,000 shares | 22,00,000 shares |
Astonea Labs IPO subscribed 1.79x in total, whereas Speciality Medicines IPO subscribed 2.27x.
| Astonea Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| QIB (times) | 0.70x | 96.24x |
| NII (times) | 5.60x | 1.88x |
| Big NII (times) | 2.50x | |
| Small NII (times) | 0.64x | |
| RII (times) | 1.69x | 0.85x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.79x | 2.27x |
